Methods for treating ovarian cancer comprising: administering to a patient and effective amount of a cannabis extract comprising CBD wherein preferably the cannabis extract is administered via a mucosal formulation.

Methods for treating ovarian cancer comprising: administering to a patient and effective amount of a cannabis extract comprising CBD wherein preferably the cannabis extract is administered via a mucosal formulation.

A therapeutic or exercise putty includes a boronated silicone elastomer serving as the base ingredient or component and CBD or CBG oil or powder, DMSO, or CBD or CBG oil or powder together with DMSO, as a secondary ingredient mixed with the base putty. The inclusion of any one of the aforementioned secondary ingredients will reduce the pain and inflammation when the putty is used for hand rehabilitation or exercise by users and patients. Added side effects of reduced stress, tension or discomfort also contribute to a positive rehabilitation exercise experience that supports better user or patient health.

Oral film formulations comprising at least one hydrophobic active agent; and a polymeric matrix at least partly composed of hydrophobic or insoluble excipients, or a combination thereof, to facilitate a controlled or sustained dissolution. Wherein when the oral film formulation has an unfavorable environment for fast dissolution, it exhibits partial disintegration within 1 to 10 minutes and a sustained rate of dissolution as confirmed by a disintegration test conducted in a limited volume petri dish, and wherein the film undergoes disintegration into smaller and smaller pieces.

An improved fibrous pellet for oral applications is disclosed herein. The fibrous pellet has improved physical and mechanical properties due to an improved manufacturing method that produces a more uniform and structurally sound fibrous pellet compared with the prior art. The fibrous pellet described herein may be configured for intra-oral delivery of active substances as well as the intra-oral absorption of fluids.

The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective effects in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with amyotrophic lateral sclerosis (ALS). Furthermore, the combination of the cannabinoid tetrahydrocannabinol (THC) with the drug olexisome provided a synergistic disease modifying effect in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with ALS.

The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective effects in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with amyotrophic lateral sclerosis (ALS). Furthermore, the combination of the cannabinoid tetrahydrocannabinol (THC) with the drug olexisome provided a synergistic disease modifying effect in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with ALS.

Compositions and methods of manufacturing mineral pitch resin compositions comprising at least one of a cannabinoid, a terpene, a terpenoid, an essential oil and a fatty acid are provided. Such mineral pitch resin compositions may be safely consumed orally, topically or otherwise, and have numerous health benefits.

Compositions and methods of manufacturing mineral pitch resin compositions comprising at least one of a cannabinoid, a terpene, a terpenoid, an essential oil and a fatty acid are provided. Such mineral pitch resin compositions may be safely consumed orally, topically or otherwise, and have numerous health benefits.

The present invention relates to a substituted resorcylic acid compound having general formula I and compositions comprising said compound for use in the activation of AMPK. The compounds are useful for the treatment or prevention of a condition, disorder or disease related to type 2 diabetes, non-alcoholic fatty liver disease and/or obesity.